Aytu BioPharma (AYTU) Stock Overview
A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AYTU Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$2.85 |
| 52 Week Low | US$0.95 |
| Beta | 0.14 |
| 1 Month Change | -9.28% |
| 3 Month Change | 6.44% |
| 1 Year Change | -20.07% |
| 3 Year Change | -60.30% |
| 5 Year Change | -99.09% |
| Change since IPO | -100.00% |
Recent News & Updates
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Jul 29
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
May 14Recent updates
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Jul 29We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
May 14Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%
May 04Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth
Jan 18Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
Nov 15Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Jun 20Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Shareholder Returns
| AYTU | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.1% | 3.6% | -1.5% |
| 1Y | -20.1% | -13.6% | 14.4% |
Return vs Industry: AYTU underperformed the US Pharmaceuticals industry which returned -13.5% over the past year.
Return vs Market: AYTU underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| AYTU volatility | |
|---|---|
| AYTU Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AYTU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AYTU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 102 | Josh Disbrow | aytubio.com |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
Aytu BioPharma, Inc. Fundamentals Summary
| AYTU fundamental statistics | |
|---|---|
| Market cap | US$19.75m |
| Earnings (TTM) | -US$1.00m |
| Revenue (TTM) | US$81.66m |
Is AYTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYTU income statement (TTM) | |
|---|---|
| Revenue | US$81.66m |
| Cost of Revenue | US$28.77m |
| Gross Profit | US$52.89m |
| Other Expenses | US$53.90m |
| Earnings | -US$1.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 64.77% |
| Net Profit Margin | -1.23% |
| Debt/Equity Ratio | 61.4% |
How did AYTU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/20 04:32 |
| End of Day Share Price | 2025/08/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aytu BioPharma, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |